Putting Science to Work

In the News

  • infd
    Clinical trials in India – Changing regulatory environment - by Dr. Chetan Tamhankar (Head -Clinical Development Services)

    Pharmabiz-01/02/2017. The recent regulatory and policy changes announced by the government has once again made clinical trials in India lucrative for the global healthcare industry.

  • infd
    Syngene International Q3 net profit up 11.54% at Rs 74 cr

    Outlook-24/01/2017. We made good progress on client service delivery across all of business verticals despite a fire incident damaging one of our research facilities, effective implementation of our business continuity plan..

  • infd
    Syngene International: Discover the chemistry

    The Hindu Businessline-30/10/2016. From a pure play research services company, catering to the research needs of innovative pharma companies, Syngene is now repositioning itself as a fully integrated contract research and manufacturing company.

  • infd
    Syngene posts 55% rise in net profit

    Live Mint-20/10/2016. Profit rose to Rs75 crore in the second quarter, from Rs48 crore a year earlier. Revenue rose 22% increase to Rs.319 crore from Rs.262 crore...

  • infd
    Syngene International acquires Strand Life Sciences’s assets.

    Live Mint-22/09/2016. Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology and pre-emptive target validation services, all of which require strong bioinformatics capabilities...

  • infd
    Syngene International Commissions Dedicated R&D Center for Amgen.

    Financial Times-06/09/2016. The state-of-the-art dedicated center will be staffed by a team of more than 100 highly qualified Syngene scientists, working in close association with Amgen researchers around the world on the discovery and development of innovative medicines...

  • infd
    Syngene Posts 28% Rise In Q1 Profit

    Profit NDTV-21/07/2016. Standalone total income from operations also rose to Rs 274.5 crore for the quarter ended June, 2016 as against Rs 233.7 crore for the year-ago..

  • infd
    Syngene Q4 profit up 18% to Rs 66 crore

    Mint-27/04/2016. The profit was notched up on a 28% increase in Syngene’s revenue to Rs334 crore from Rs254 crore

  • infd
    Syngene Q3 profit jumps 31% to Rs 59 cr.

    Business Standard-21/01/2016. Syngene reported a 31% jump in third quarter profits to Rs 59 crore and 23% growth in revenues to Rs 281 crore on improved business from its global clients to help build new drug discovery.

  • infd
    India has 'natural potential to grow' in CRO space, says Syngene CEO

    Outsourcing Pharma-14/01/2016. An exclusive interview with Peter Bains- CEO ,Syngene International Ltd -

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

FB Side
Inactive